PSEG Q3 2026 slides: nuclear output rises, operating earnings up 2%

PSEG reported Q3 2026 non-GAAP operating earnings of $1.15 per share, below the $1.19 estimate, and revenue of $3.02 billion versus $3.19 billion expected; shares fell 1.35% to $73.24. The company reaffirmed 2026 guidance of $4.28–$4.40 per share and its 6%–8% long-term earnings growth target through 2030. Year-to-date operating earnings rose to $3.56 per share from $3.33, while PSEG maintained its $24–$28 billion capital plan and reported Q3 nuclear fleet capacity factor of 95.5%.

Analysis

PEG’s key tension is not the quarterly miss itself, but whether regulated investment converts into timely earnings while the generation business carries meaningful noise and uncontracted optionality. Near term, the Power segment’s GAAP loss is a poor proxy for recurring economics given the stated mark-to-market and trust-fund effects; however, the regulated segment’s slight year-over-year earnings decline means the utility engine did not offset the headline miss this quarter. The more important 1–3 month catalyst is the expected New Jersey filing to recover regulatory lag: a constructive filing and credible recovery timetable could support the rate-base narrative, while delay or a weak proposal would expose the gap between capital spending and realized returns.

Over 6–18 months, nuclear capacity uprates, license extensions, and data-center contracting could add value, but these are not yet equivalent to contracted cash flows. High hedging limits immediate merchant-price sensitivity; the market may be assigning too much weight to prospective premium contracts before terms, counterparties, and regulatory treatment are clear. Conversely, the maintained growth outlook and no-equity funding claim deserve scrutiny against 60% debt-to-capitalization and the company’s financing needs: higher rates, weaker cash generation, or regulatory lag could increase debt reliance and constrain equity returns. The February 2027 outlook update is the next meaningful test. Falsify the cautious view if the filing accelerates recovery and guidance is met without deterioration in credit metrics; strengthen it if guidance is cut, financing rises, or regulatory recovery slips.

Key Decisions for Investors

• No immediate event-driven position: the modest miss is not enough to establish a durable earnings downgrade, while the nuclear upside remains largely conditional.
• Watch for the New Jersey rate-recovery filing and quantify the proposed revenue recovery against recent capital additions before adding PEG; a delayed or diluted filing is a reason to reduce exposure.
• Treat data-center nuclear contracting and capacity-uprate claims as catalysts, not base-case earnings. Reassess only when counterparties, pricing, volumes, and regulatory approval are disclosed.
• At the February 2027 update, test the 6–8% growth trajectory against financing needs, debt metrics, and rate-case timing. A guidance reduction or materially higher financing requirement would invalidate the growth thesis.